Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cybele Woon

Ophthalmology Houston, TX Medical Doctor

NPI 1487738878 CMS profile 22139

1237 Campbell Rd, Houston, TX 77055

Open in the dashboard

General payments

$5,491

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cybele Woon of Houston, TX is reported in the CMS Open Payments database as having received $5,491 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $636 27
2024 General $1,301 36
2023 General $988 28
2022 General $420 21
2021 General $850 30
2020 General $873 25
2019 General $423 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cybele Woon
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Cybele Woon were reported at $636. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Cybele Woon Ophthalmology median Middle half National median
2019 $423 $258 $104–$655 $163
2020 $873 $126 $45–$321 $114
2021 $850 $205 $76–$534 $132
2022 $420 $266 $100–$678 $149
2023 $988 $308 $117–$745 $160
2024 $1,301 $340 $127–$846 $164
2025 $636 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $896 37 payments
  2. Merz North America, Inc. $627 12 payments
  3. Glaukos Corporation $446 4 payments
  4. Alexion Pharmaceuticals, Inc. $395 14 payments
  5. Allergan Inc. $394 18 payments
  6. UCB, Inc. $387 12 payments
  7. Alcon Vision LLC $331 6 payments
  8. Sun Pharmaceutical Industries Inc. $296 15 payments
  9. Kala Pharmaceuticals, Inc. $231 7 payments
  10. Bausch & Lomb, a division of Bausch Health US, LLC $196 11 payments
  11. Other $1,292 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,491 189 payments
Products named General payments · program years 2019–2025
  1. ULTOMIRIS $354 12 payments
  2. BOTOX Botox Therapeutic $337 14 payments
  3. Rystiggo $336 10 payments
  4. BOTOX Hyperhydrosis $323 14 payments
  5. CE-marked KXLA system $307 3 payments
  6. LUMIGAN $250 10 payments
  7. Xelpros $228 12 payments
  8. Cequa $198 10 payments
  9. EYSUVIS $174 4 payments
  10. QULIPTA $162 7 payments
  11. Other $3,667 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

578

Median for Ophthalmology: 891

Drug cost

$32,509

Median for Ophthalmology: $68,233

Branded share of claims

26.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 46 $18,502
Simbrinza Brinzolamide/Brimonidine Tart Brand 11 $2,118
Latanoprost Generic 173 $1,954
Pyridostigmine Bromide Generic 28 $1,914
Travoprost Generic 15 $1,871
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 11 $1,450
Timolol Maleate Generic 85 $1,093
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 54 $1,056
Valacyclovir Valacyclovir Hcl Brand 19 $902
Prednisone Generic 79 $647

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$155,236

Of which drugs: $26,473

Medicare patients

768

Average age 75

Services billed

7,318

464 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 33%
Diabetes 26%
Osteoporosis 19%
Chronic kidney disease 18%
Depression 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 18 5,780 $26,473

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Rystiggo
  • UCB, Inc. $275
$275 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $160
$160 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $98
$98 — —
BOTOX
  • AbbVie, Inc. $80
$80 — 5,780
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record